1192 related articles for article (PubMed ID: 2107007)
21. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.
Fyles GM; Messner HA; Lockwood G; Curtis JE; Rider W; Minden MD; Meharchand JM; Lipton J; Tritchler D; Van Dyk J
Bone Marrow Transplant; 1991 Dec; 8(6):453-63. PubMed ID: 1790425
[TBL] [Abstract][Full Text] [Related]
23. Fractionated total body irradiation and high-dose VP-16 with purged autologous bone marrow rescue for children with high risk relapsed acute lymphoblastic leukemia.
Schmid H; Henze G; Schwerdtfeger R; Baumgarten E; Besserer A; Scheffler A; Serke S; Zingsem J; Siegert W
Bone Marrow Transplant; 1993 Dec; 12(6):597-602. PubMed ID: 8136744
[TBL] [Abstract][Full Text] [Related]
24. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients.
Cahn JY; Bordigoni P; Souillet G; Pico JL; Plouvier E; Reiffers J; Benz-Lemoine E; Bergerat JP; Lutz P; Colombat P
Bone Marrow Transplant; 1991 Jan; 7(1):1-4. PubMed ID: 2043871
[TBL] [Abstract][Full Text] [Related]
25. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
26. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.
Mehta J; Powles R; Singhal S; Horton C; Tait D; Treleaven J
Bone Marrow Transplant; 1996 Jul; 18(1):119-23. PubMed ID: 8832004
[TBL] [Abstract][Full Text] [Related]
27. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Matsue K; Tohi T; Masauji N; Tsukuda K
Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
Rubin CM; Mick R; Johnson FL
Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
[TBL] [Abstract][Full Text] [Related]
30. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
32. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
[TBL] [Abstract][Full Text] [Related]
33. [Allogeneic bone marrow transplantation in the treatment of acute leukemias of children. Study of 26 patients].
Michel G; Maraninchi D; Perrimond H; Mascret B; Orsini A; Gastaut JA; Raybaud C; Blaise D; Demeocq F; Sebahoun G
Arch Fr Pediatr; 1986 Dec; 43(10):769-74. PubMed ID: 3548633
[TBL] [Abstract][Full Text] [Related]
34. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy.
Wagner JE; Vogelsang GB; Zehnbauer BA; Griffin CA; Shah N; Santos GW
Bone Marrow Transplant; 1992 Mar; 9(3):205-9. PubMed ID: 1511257
[TBL] [Abstract][Full Text] [Related]
35. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
36. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
Kröger N; Hoffknecht M; Hänel M; Krüger W; Zeller W; Stockschläder M; de Wit M; Weh HJ; Kabisch H; Erttmann R; Zander AR
Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
[TBL] [Abstract][Full Text] [Related]
37. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
38. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
Marks DI; Forman SJ; Blume KG; Pérez WS; Weisdorf DJ; Keating A; Gale RP; Cairo MS; Copelan EA; Horan JT; Lazarus HM; Litzow MR; McCarthy PL; Schultz KR; Smith DD; Trigg ME; Zhang MJ; Horowitz MM
Biol Blood Marrow Transplant; 2006 Apr; 12(4):438-53. PubMed ID: 16545728
[TBL] [Abstract][Full Text] [Related]
39. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
